Welcome to our dedicated page for Scienture Holdings SEC filings (Ticker: SCNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scienture Holdings, Inc. (NASDAQ: SCNX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, proxy materials and registration-related documents. Scienture files with the U.S. Securities and Exchange Commission as a Delaware corporation under Commission File Number 001-39199, and its filings offer detailed insight into its specialty pharmaceutical business conducted through its wholly owned subsidiary, Scienture, LLC.
Among the most informative documents for SCNX are current reports on Form 8-K, which describe material events such as financing arrangements, amendments to debt agreements, conversion of secured convertible debentures into common stock, and the issuance of senior secured promissory notes. These filings outline key terms such as principal amounts, original issue discounts, interest rates, security agreements granting liens on company and subsidiary assets, and guaranty obligations. Other 8-Ks address corporate actions including amendments to bylaws, notices from Nasdaq regarding minimum bid price compliance, and results of stockholder votes at the annual meeting.
Scienture’s definitive proxy statement on Schedule 14A is another core filing, setting out proposals submitted to stockholders, including director elections, potential increases in authorized share capital, amendments to the company’s equity incentive plan, authorization for a potential future offering of common stock under Nasdaq Listing Rule 5635(d), and possible reverse stock split authority. The proxy statement also explains governance structures, committee charters and procedures for the annual meeting.
Through Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand complex topics such as capital structure changes, equity distribution agreements on Form S-3, or listing compliance matters. Users can review historical and recent filings, monitor how Scienture manages its financing and governance, and reference official disclosures related to its specialty products, including Arbli™ and REZENOPY™. This page is a resource for investors seeking structured, regulator-reviewed information on SCNX beyond press releases and market commentary.
Scienture Holdings, Inc. (SCNX) is calling a virtual 2026 annual stockholders meeting on October 28, 2026 to elect five directors for one-year terms, ratify CM3 Advisory as independent auditor for 2026, hold an advisory "say‑on‑pay" vote, and approve potential adjournment to solicit additional proxies if needed.
The proposed board consists of Executive Chairman and Co‑CEO Shankar Hariharan, Co‑CEO/President/Interim CFO Narasimhan Mani, and three independent directors: Mayur Doshi, Donald G. Fell, and Subbarao Jayanthi. All three key board committees (audit, compensation, and nominating/governance) are composed entirely of independent directors, with Doshi serving as audit chair and Fell as compensation and nominating/governance chair.
CM3 Advisory billed $138,585 of audit fees in 2025 versus $268,628 in 2024, with 2024 also including $57,149 of tax and other fees. 2025 total compensation was $1,265,169 for Co‑CEO Mani and $1,165,169 for Co‑CEO Hariharan, largely from stock awards. Each holds 1,050,000 unvested shares with a stated market value of $535,500.
Scienture Holdings, Inc. (SCNX) filed an initial insider ownership report for its Chief Financial Officer, Eric Michael Sherb. The filing states that as of March 13, 2025, he does not beneficially own any securities of Scienture Holdings, Inc., and reports direct ownership of 0 shares following the reported position.
Scienture Holdings, Inc. (SCNX) reported strong improvement for the quarter ended June 30, 2026, highlighted by a sharp ramp in commercialization. Q2 2026 revenue was $343,639, up about 510% sequentially from Q1 2026 and compared with no revenue in Q2 2025, with a Q2 gross margin of about 97.7%. First-half 2026 revenue reached $399,964, versus $10,258 in the prior-year period.
Operating expenses fell about 41% year-over-year in Q2 to roughly $3.0 million, improving operating loss to about $2.7 million from $5.2 million. Q2 net loss narrowed to about $2.8 million (basic and diluted loss per share $0.07) from $6.7 million ($0.48 per share) a year earlier. As of June 30, 2026, cash, cash equivalents and restricted cash totaled approximately $11.2 million, up from about $6.7 million at December 31, 2025.
Operationally, Scienture commenced the commercial launch of REZENOPY™, its second commercial product, while expanding payer coverage for Arbli™, including adding about 12.5 million covered lives. New U.S. patents were granted for both REZENOPY and Arbli, extending intellectual property protection and expected market exclusivity through 2041.
Scienture Holdings, Inc. reported early commercialization progress in branded specialty pharma for the quarter ended June 30, 2026. Revenue reached $343,639 for the quarter and $399,964 for the first half of 2026, up from minimal sales in 2025, driven entirely by ARBLI™ (SCN-102) losartan oral suspension. Gross profit was $335,779 in Q2.
The company remains loss-making but its quarterly net loss narrowed to $2.8 million from $6.7 million a year earlier; first-half net loss was $6.2 million versus $9.8 million in 2025. Operating expenses were $3.0 million in Q2, including $1.2 million of research and development focused on pipeline assets SCN-102, SCN-104 and SCN-106.
At June 30, 2026, Scienture held $8.2 million in cash and equivalents plus $3.0 million in restricted cash, total assets of $87.7 million and working capital of about $6.2 million. Intangible assets tied to its four product technologies totaled $70.1 million after prior-year goodwill and IPR&D impairments. New Streeterville secured notes provided $10.6 million of net debt financing in 2026, leaving total liabilities at $23.6 million. Management acknowledges prior substantial doubt about going concern but believes current liquidity, ARBLI™ revenues, the planned launch of SCN-110 and potential capital raises support operations for at least 12 months.
Scienture Holdings, Inc. reported that its Chief Financial Officer, Eric Sherb, resigned effective May 26, 2026. He informed the company that he was leaving for personal reasons and that his decision was not related to any dispute or disagreement with management or the board.
On the same date, the company appointed Dr. Narasimhan Mani, age 51, as Interim Chief Financial Officer. Dr. Mani already serves as Co-Chief Executive Officer, President, and a director, and has been overseeing operations including financial planning, revenue and expense management, and financial reporting.
The disclosure highlights Dr. Mani’s more than 25 years of pharmaceutical industry experience, his prior senior roles at several life sciences companies, and his advanced degrees including an MBA in Finance and Marketing from Columbia Business School. His service as Interim CFO will continue under his existing employment agreement previously filed with the SEC.
Scienture Holdings, Inc. reported very early-stage commercial results for the quarter ended March 31, 2026. Revenue rose to about $56 thousand, up roughly 449% from the prior-year quarter, as sales of its SCN-102/Arbli losartan oral suspension ramped.
Gross profit increased to about $54 thousand and gross margin expanded sharply to roughly 95.6%, while total operating expenses stayed roughly flat at about $3.56 million. The company posted a net loss of about $3.4 million, slightly higher than a year earlier.
Operationally, Scienture highlighted new patent protection for Arbli, an Orange Book–listable patent for REZENOPY 10 mg naloxone nasal spray, expanded GPO agreements giving REZENOPY access to over 5,000 healthcare institutions, and an additional $11.0 million in non-dilutive debt financing to support commercialization and its R&D pipeline.
Scienture Holdings, Inc. posted modest early commercialization revenue while continuing to generate sizable losses in the quarter ended March 31, 2026. Revenue rose to $56,325, driven entirely by initial sales of ARBLI™ (SCN-102), but the company recorded a net loss of $3.4 million and an operating loss of $3.5 million.
Cash and cash equivalents were $3.54 million with positive working capital of about $1.97 million, versus an accumulated deficit of $83.95 million. Intangible assets tied to the Scienture pipeline totaled roughly $70.5 million after prior impairments, with SCN-102 now amortizing over 13 years.
Management highlights substantial doubt about the company’s ability to continue as a going concern, relying on ARBLI™ commercialization, tight cost control, and access to additional capital. After quarter-end, Scienture entered into new secured Streeterville notes totaling $11.42 million, funding $8.0 million immediately and placing $3.0 million in a controlled account, secured by substantially all assets.
Scienture Holdings, Inc. furnished an updated investor presentation on its website on May 5, 2026 and attached it as Exhibit 99.1 to this report. The presentation is intended for meetings with analysts, potential investors, and other interested parties and should be read together with the company’s SEC filings.
The material in the presentation and this report is furnished under Regulation FD, is not deemed “filed,” and is not incorporated into other SEC filings unless specifically referenced. Scienture also includes typical cautionary language about forward-looking statements and refers readers to risk discussions in its Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
Scienture Holdings, Inc. entered into and closed a note purchase agreement with Streeterville Capital, LLC, issuing two secured promissory notes: a Secured Promissory Note A-1 with an original principal amount of $8.42 million and a Secured Promissory Note B with an original principal amount of $3 million.
The A-1 Note carries a $400,000 original issue discount and $20,000 in transaction costs, bears 9% annual interest and matures in eighteen months; the Lender funded $8 million at closing. The B Note bears 5% annual interest, matures in eighteen months, and $3 million was deposited into a controlled account of a newly formed subsidiary under a Deposit Account Control Agreement.
Both notes are secured by security agreements, a guaranty, and a pledge of subsidiary equity, contain detailed Major and Minor Trigger Events that can increase outstanding balances by up to 25%, and allow Monthly Redemptions up to $175,000 and Limited Redemptions tied to trading volume and price conditions.
Scienture Holdings, Inc. files an amended annual report that keeps 2025 results and governance details together in one place while correcting immaterial MD&A errors and adding Part III information. For 2025, the company generated revenue of $431,609, mainly from initial ARBLI™ sales, but recorded a net loss of $41,512,264 driven by $26,346,050 of non-cash impairment charges and higher financing costs.
Cash and cash equivalents were $6,662,008 as of December 31, 2025, with positive working capital of approximately $5,181,000, and management concluded there is no substantial doubt about the company’s ability to continue as a going concern for at least twelve months. Operations are being refocused on Scienture LLC’s branded and specialty pharmaceutical pipeline, funded in part by approximately $26,293,039 of 2025 equity proceeds and divestitures of legacy businesses.